Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

María-Victoria Mateos

Showing results (1-10 of 286) with videos related to

Pageof 29
Sort By:
Cancer Treatment Reviews|May 18, 2010
Management of treatment-related adverse events in patients with multiple myelomaMaría-Victoria Mateos
Leukemia Research|November 27, 2012
How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse eventsMaría-Victoria Mateos
Expert Review of Hematology|November 19, 2010
Role of bortezomib for the treatment of previously untreated multiple myelomaMaría-Victoria Mateos
The Lancet. Oncology|April 22, 2011
Subcutaneous bortezomib: a step towards optimised drug useMaría-Victoria Mateos
Clinical Advances in Hematology & Oncology : H&O|October 18, 2017
When to initiate treatment in smoldering multiple myelomaMaría-Victoria Mateos
Expert Review of Hematology|November 4, 2014
Management of asymptomatic myeloma patientsMaría-Victoria Mateos
The New England Journal of Medicine|May 29, 2026
Redefining Early Relapse in Multiple Myeloma - Time to Change the RulesMaría-Victoria Mateos
Current Opinion in Oncology|September 12, 2014
Advances in the management of asymptomatic myelomaMaría-Victoria Mateos
The New England Journal of Medicine|October 9, 2024
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. ReplyVania Hungria, María-Victoria Mateos
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2025
Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point?María-Victoria Mateos, Noemí Puig
Pageof 29

Showing results (1-10 of 286) with videos related to

Sort By:
Pageof 29
Cancer Treatment Reviews|May 18, 2010
Management of treatment-related adverse events in patients with multiple myelomaMaría-Victoria Mateos
Leukemia Research|November 27, 2012
How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse eventsMaría-Victoria Mateos
Expert Review of Hematology|November 19, 2010
Role of bortezomib for the treatment of previously untreated multiple myelomaMaría-Victoria Mateos
The Lancet. Oncology|April 22, 2011
Subcutaneous bortezomib: a step towards optimised drug useMaría-Victoria Mateos
Clinical Advances in Hematology & Oncology : H&O|October 18, 2017
When to initiate treatment in smoldering multiple myelomaMaría-Victoria Mateos
Expert Review of Hematology|November 4, 2014
Management of asymptomatic myeloma patientsMaría-Victoria Mateos
The New England Journal of Medicine|May 29, 2026
Redefining Early Relapse in Multiple Myeloma - Time to Change the RulesMaría-Victoria Mateos
Current Opinion in Oncology|September 12, 2014
Advances in the management of asymptomatic myelomaMaría-Victoria Mateos
The New England Journal of Medicine|October 9, 2024
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. ReplyVania Hungria, María-Victoria Mateos
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2025
Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point?María-Victoria Mateos, Noemí Puig
Pageof 29